PatternsRadar
Sign in

ALIVUSAlivus Life Sciences Limited

NSE
Full chart
1,384.00INR+10.30 (+0.75%)Close · 6 Oct 2026
30 Jul 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹16,992 CrMarket cap
28.2P/E (TTM)
68.8%Delivery

Filings & corporate actions

21 results filed
CSV
Next results · Q2 FY27
Expected 20 Oct 2026 – 11 Nov 2026
Estimate: filed 20–42 days after quarter end, last 5 times
Dividend
₹5.00 per share · last 1 Sept 2026
2026
  • 1 SeptdividendDividend · ₹5.00 per share+2.7%
  • 30 JulresultsResults · Q1 FY27 · standalone+5.9%NSE
  • 13 JulshareholdingShareholding · 30 Jun 20260.0%NSE
  • 14 MayresultsResults · Q4 FY26 · standalone-1.8%NSE
  • 14 AprshareholdingShareholding · 31 Mar 2026+1.8%NSE
  • 22 JanresultsResults · Q3 FY26 · standalone+2.6%NSE
  • 19 JanshareholdingShareholding · 31 Dec 2025-1.8%NSE

Reaction to results · all yearsrose on day 0 in 9 of 21 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2730 Jul 2026+5.9%+21.4%+23.2%2.8×
Q4 FY2614 May 2026-1.8%-2.4%-1.2%1.8×
Q3 FY2622 Jan 2026+2.6%+6.2%+5.7%3.3×
Q2 FY266 Nov 2025+2.8%+1.6%-0.8%1.6×
Q1 FY261 Aug 2025-3.5%-7.3%-6.3%1.6×
Q4 FY2515 May 2025-5.3%-7.4%-15.9%2.1×
Q3 FY2523 Jan 2025-1.5%+2.9%-9.6%2.0×
Q2 FY2524 Oct 2024-9.9%+1.0%+2.6%2.7×
Q1 FY2525 Jul 2024-2.9%+0.9%+18.0%1.3×
Q4 FY2425 Apr 2024+8.6%+10.7%+10.9%5.5×
Q3 FY2423 Jan 2024+1.2%+8.4%+11.1%1.0×
Q2 FY2420 Oct 2023-0.7%+0.2%+0.3%0.5×
Q1 FY2421 Jul 2023+0.1%+5.6%+0.8%1.7×
Q4 FY2328 Apr 2023+5.2%+12.8%+13.5%10.3×
Q3 FY2327 Jan 2023-0.8%-3.6%-3.7%1.1×
Q2 FY2322 Oct 2022+3.2%+7.1%+2.9%0.3×
Q1 FY235 Aug 2022-0.6%-1.2%-2.6%1.0×
Q4 FY2221 Apr 2022-0.1%-1.6%-9.9%1.0×
Q3 FY228 Feb 2022-2.3%-8.1%-19.0%2.5×
Q2 FY2211 Nov 2021+2.9%-1.1%-2.7%3.2×
Q1 FY2213 Aug 2021-3.2%-11.8%-6.0%—
Average-0.0%+1.6%+0.5%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+6.4%
Profit YoY+31.7%
Interest cost YoY+63.9%
Revenue QoQ-7.1%
Profit QoQ-1.6%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+6.3%+4.8%+5.5%———
Profit+16.2%+6.9%+9.0%———

Key data

CSV
Open1,365.40
Day range1,354.20 – 1,394.70
52-week range819.00 – 1,493.80
From 52w high-7.4%
RSI (14)53.6
ATR (14)48.12
Volume1.67L
Avg volume (20D)1.30L
Rel volume1.29×
Volatility (1Y)28.0%
Turnover₹23.1Cr
SMA 50 / 2001,346.80 / 1,087.26

Delivery percentage

Latest · 6 Oct 202668.8%
20-day avg54.4%
1-year avg53.0%
Percentile (own history)85th
Range6.1–94.3%
Sessions1,276

Over the last 20 sessions ALIVUS settled 54.4% of its traded quantity, which is above average for an NSE equity. That is in line with its own one-year average of 53.0%. The latest session ranks higher than 85% of the 1,276 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+0.75%+2.86%-2.45%+20.91%+39.85%+47.36%

Valuation

CSV
Market cap₹16,992 Cr
P/E (TTM)28.2
EPS (TTM)49.12
Shares outstanding12.27Cr
Listed6 Aug 2021

Ownership

CSV
Promoter74.87%
Promoter Δ QoQ0.00 pp
Public25.13%
FII5.54%
DII7.18%
Pledged0.00%

Quarterly results · standalone

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)588.0672.9689.1640.4
YoY chg+16.0%+4.8%+6.1%+6.4%
Net profit (₹ Cr)130.0150.3162.7160.1
YoY chg+36.4%+9.7%+14.7%+31.7%
Net margin22.1%22.3%23.6%25.0%
EPS10.5812.2213.2213.01

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 74.87% · public 25.13%
5 Aug 2021: promoter 82.84%30 Sept 2021: promoter 82.84%31 Dec 2021: promoter 82.84%31 Mar 2022: promoter 82.85%30 Jun 2022: promoter 82.85%30 Sept 2022: promoter 82.85%31 Dec 2022: promoter 82.85%31 Mar 2023: promoter 82.85%30 Jun 2023: promoter 82.85%30 Sept 2023: promoter 82.85%31 Dec 2023: promoter 82.85%31 Mar 2024: promoter 82.85%30 Jun 2024: promoter 82.85%30 Sept 2024: promoter 75.00%31 Dec 2024: promoter 75.00%31 Mar 2025: promoter 74.99%30 Jun 2025: promoter 74.94%30 Sept 2025: promoter 74.91%31 Dec 2025: promoter 74.91%31 Mar 2026: promoter 74.87%30 Jun 2026: promoter 74.87%
2021-082026-06
  • Promoter
  • Public and others
Promoter
74.87%
Public
25.13%
Promoter change
0.00 pp
Filed
13 Jul 2026
FII
5.54%
DII
7.18%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
Standalone
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations595.4572.8536.6588.6506.9641.8649.5601.8588.0672.9689.1640.4
Other income5.41.73.15.58.510.510.19.014.713.922.822.4
Total income600.7574.5539.7594.1515.4652.3659.6610.8602.7686.8711.9662.8
Total expenses441.8413.8410.0443.9388.0467.2468.3447.9428.6462.8496.1450.6
└ Finance costs0.40.40.40.40.30.51.31.31.31.51.31.3
└ Depreciation13.113.214.514.415.115.216.017.118.419.720.220.6
Profit before tax158.9160.7129.7150.2127.5185.1191.3163.0174.1198.4215.8212.2
Tax expense40.241.931.738.832.148.249.441.444.148.153.152.1
Net profit118.7118.897.9111.595.3137.0141.9121.5130.0150.3162.7160.1
EPS9.699.697.999.107.7811.1811.579.9110.6012.2513.2313.04
Net margin19.94%20.73%18.25%18.94%18.80%21.34%21.84%20.19%22.11%22.33%23.60%25.00%
PBT margin26.69%28.05%24.17%25.52%25.15%28.85%29.45%27.08%29.62%29.48%31.32%33.14%
Tax rate25.29%26.09%24.48%25.80%25.22%26.03%25.84%25.43%25.33%24.26%24.62%24.57%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 30 Jul 2026.

ALIVUS at a glance

  • ALIVUS closed at ₹1,384 on 6 Oct 2026, +0.75% on the day, +47.4% over one year, 7.4% below its 52-week high of ₹1,493.8.
  • Delivery was 68.8% of traded quantity on 6 Oct 2026, the 85th percentile of its own 1,276 sessions with a reading (20-session average 54.4%, 1-year average 53.0%).
  • Market capitalisation is ₹16,992 crore at a trailing P/E of 28.2 (trailing EPS ₹49.12).
  • Q1 FY27 results (standalone, filed 30 Jul 2026): revenue ₹640 crore (+6.4% year on year), net profit ₹160 crore (+31.7%); the price moved +5.9% on the first session after.
  • Promoters held 74.87% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 20 Oct 2026 and 11 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE03Q201024
SeriesEQ
Listed6 Aug 2021
History from6 Aug 2021
Sessions1,280
Turnover rank#823

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE